1. Home
  2. TSLX vs GLPG Comparison

TSLX vs GLPG Comparison

Compare TSLX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSLX
  • GLPG
  • Stock Information
  • Founded
  • TSLX 2010
  • GLPG 1999
  • Country
  • TSLX United States
  • GLPG Belgium
  • Employees
  • TSLX N/A
  • GLPG N/A
  • Industry
  • TSLX Investment Managers
  • GLPG Biotechnology: Pharmaceutical Preparations
  • Sector
  • TSLX Finance
  • GLPG Health Care
  • Exchange
  • TSLX Nasdaq
  • GLPG Nasdaq
  • Market Cap
  • TSLX 2.2B
  • GLPG 1.8B
  • IPO Year
  • TSLX 2014
  • GLPG 2005
  • Fundamental
  • Price
  • TSLX $23.49
  • GLPG $26.74
  • Analyst Decision
  • TSLX Strong Buy
  • GLPG Sell
  • Analyst Count
  • TSLX 7
  • GLPG 5
  • Target Price
  • TSLX $22.79
  • GLPG $26.75
  • AVG Volume (30 Days)
  • TSLX 417.3K
  • GLPG 355.9K
  • Earning Date
  • TSLX 02-13-2025
  • GLPG 02-12-2025
  • Dividend Yield
  • TSLX 8.86%
  • GLPG N/A
  • EPS Growth
  • TSLX N/A
  • GLPG N/A
  • EPS
  • TSLX 2.03
  • GLPG 1.16
  • Revenue
  • TSLX $482,526,000.00
  • GLPG $285,380,474.00
  • Revenue This Year
  • TSLX N/A
  • GLPG $2.78
  • Revenue Next Year
  • TSLX N/A
  • GLPG $1.62
  • P/E Ratio
  • TSLX $11.58
  • GLPG $23.02
  • Revenue Growth
  • TSLX 10.14
  • GLPG 14.99
  • 52 Week Low
  • TSLX $19.50
  • GLPG $22.36
  • 52 Week High
  • TSLX $23.66
  • GLPG $37.22
  • Technical
  • Relative Strength Index (RSI)
  • TSLX 80.47
  • GLPG 71.20
  • Support Level
  • TSLX $21.93
  • GLPG $26.49
  • Resistance Level
  • TSLX $23.15
  • GLPG $27.48
  • Average True Range (ATR)
  • TSLX 0.34
  • GLPG 0.66
  • MACD
  • TSLX 0.09
  • GLPG 0.54
  • Stochastic Oscillator
  • TSLX 90.20
  • GLPG 85.55

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Share on Social Networks: